NAGENiagen Bioscience Inc

$423M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$84M+16.0% YoY

Gross Profit

$51M60.8% margin

Operating Income

-$6M-6.7% margin

Net Income

-$5M-5.9% margin

EPS (Diluted)

$-0.07

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$7M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$55M

Total Liabilities

$27M

Stockholders' Equity

$28M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$84M	$72M	+16.0%
Gross Profit	$51M	$43M	+18.7%
Operating Income	-$6M	-$19M	+69.9%
Net Income	-$5M	-$17M	+70.1%

NAGE FY 2023 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena